Skip Navigation

AIDSInfo logo

 
Home > Drugs > Rilpivirine (TMC278)

Rilpivirine (TMC278)
Drug Class: Non-nucleoside Reverse Transcriptase Inhibitors
TMC278 is a type of medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRTIs work by blocking reverse transcriptase, a protein that HIV needs to make more copies of itself.

HIV/AIDS-Related Uses
TMC278 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the treatment of HIV infection. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

Dosage Form/Administration
TMC278 comes in tablet form and should be taken once daily by mouth with food.

Recommended Daily Dose
TMC278 has been studied in 75, 125, and 150 mg daily dosages. The 75 mg daily dosage has been selected for development in treatment-naive people; the other dosages are still being studied for use in other HIV infected people.

Contraindications
Individuals should tell a doctor about any medical problems before taking this medicine.

Possible Side Effects
Along with its desired effects, TMC278 may cause some unwanted effects. Although not all of these effects are known, headache, fatigue, and nausea have been reported.

Drug and Food Interactions
A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.

Clinical Trials
Click here to search ClinicalTrials.gov for trials that use Rilpivirine (TMC278).

Manufacturer Information
Rilpivirine (TMC278)
  Tibotec
  1029 Stony Hill Road
  Suite 300
  Yardley,  PA  19067
  (877) 732-2488
    
Updated June 21, 2007